Fate Therapeutics up after ASH presentation attracts attention

 

• Fate Therapeutics (NASDAQ:FATE) trades higher after a presentation over the weekend at the ASH conference on FT516 data.
• "Given the heavily pretreated nature of these patients, we believe FT516 played a dominant role in the combination’s activity, further de-risking iNK cells as a therapeutic modality. In our view, these data showcase the therapeutic potential of Fate's PSC-NK pipeline, and will likely attract additional investor interest," updates Oppenheimer analyst Matthew Biegler.
• The firm keeps an Outperform rating on Fate and boosts its price target to $70 from $60.
• https://seekingalpha.com/news/3642071-fate-therapeutics-jumps-9-after-ash-presentation-attracts-attention